For research use only. Not for therapeutic Use.
ASLAN003 (Cat No.:I017943) is a small-molecule inhibitor that specifically targets Dihydroorotate Dehydrogenase (DHODH), an enzyme involved in the de novo pyrimidine synthesis pathway. By inhibiting DHODH, ASLAN003 disrupts pyrimidine nucleotide production, leading to the depletion of intracellular pyrimidine pools and impairing cancer cell proliferation and survival. With its potential to inhibit cancer cell growth, ASLAN003 holds promise as a therapeutic option for various cancers, including hematological malignancies and solid tumors. Clinical trials are underway to evaluate its efficacy and safety, paving the way for potential applications in cancer treatment where DHODH inhibition can be beneficial.
| Catalog Number | I017943 |
| CAS Number | 1035688-66-4 |
| Molecular Formula | C₁₉H₁₄F₂N₂O₃ |
| Purity | ≥95% |
| IUPAC Name | 2-[2,6-difluoro-4-(3-methoxyphenyl)anilino]pyridine-3-carboxylic acid |
| InChI | InChI=1S/C19H14F2N2O3/c1-26-13-5-2-4-11(8-13)12-9-15(20)17(16(21)10-12)23-18-14(19(24)25)6-3-7-22-18/h2-10H,1H3,(H,22,23)(H,24,25) |
| InChIKey | OMPATGZMNFWVOH-UHFFFAOYSA-N |
| SMILES | COC1=CC=CC(=C1)C2=CC(=C(C(=C2)F)NC3=C(C=CC=N3)C(=O)O)F |
| Reference | [1]. Jianbiao Zhou, et al. ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. Haematologica. 2019 Nov7;haematol.2019.230482.<br>[2]. Marco L. Lolli, et al. Human Dihydroorotate Dehydrogenase (hDHODH) as a new target on Acute Myelogenous Leukemia (AML): Targeting Myeloid Differentiation using Potent and Innovative hDHODH Inhibitors. 23rd Swedish Conference on Macromolecular Structure and Function Tällberg, 14-17 June 2019 |
